Epirubicin in patients with liver dysfunction - development and evaluation of a novel dose modification scheme

By Dobbs N.A.   Twelves C.J.   Gregory W.   Cruickshanka C.   Richards M.A.   Rubens R.D.  

European Journal of Cancer, Vol. 39, Iss. 5, 2003-03 ,pp. : 580-586

Elsevier

Access to resources Recommend Favorite

Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer

By Fountzilas George   Pectasides Dimitrios   Christodoulou Christos   Timotheadou Eleni   Economopoulos Theofanis   Papakostas Pavlos   Papadimitriou Christos   Gogas Helen   Efstratiou Ioannis   Skarlos Dimosthenis  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 479-488

Humana Press, Inc

Access to resources Recommend Favorite

Practical management of classical myeloproliferative disorder patients: a clinician’s guide

By Mesa Ruben A  

Future Oncology, Vol. 2, Iss. 4, 2006-08 ,pp. : 515-524

Future Medicine

Access to resources Recommend Favorite

Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study

By Palumbo R.   Neumaier C.   Cosso M.   Bertero G.   Raffo P.   Spadini N.   Valente S.   Villani G.   Pastorino M.   Toma S.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 66-72

Elsevier

Access to resources Recommend Favorite

Pharmacokinetics of anticancer agents in patients with impaired liver function

By Donelli M.G.   Zucchetti M.   Munzone E.   D'Incalci M.   Crosignani A.  

European Journal of Cancer, Vol. 34, Iss. 1, 1998-01 ,pp. : 33-46

Elsevier

Access to resources Recommend Favorite